← Back to Search

Screening Tests for Cervical and Anal Cancer in HIV Patients (CAMPO-101 Trial)

N/A
Recruiting
Led By Joel Palefsky, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial uses quick tests to find abnormal tissue changes in the cervix or anus in men and women with HIV. These patients are at higher risk for HPV-related cancers. The tests help detect early signs of potential cancer so that further checks and treatments can be done if needed.

Who is the study for?
This trial is for adults over 21 with HIV who have not had a hysterectomy, are not pregnant or recently post-partum, and haven't been treated for related lesions in the last 18 months. They must understand the study and agree to participate, have an ECOG performance status of <=1 (or Karnofsky >=70%), documented HIV infection, and be on antiretroviral therapy.
What is being tested?
The trial tests various screening methods like biopsies and imaging techniques to detect high-grade squamous intraepithelial lesions (HSIL) that could lead to cervical or anal cancer in people with HIV. It aims to identify which screenings work best for early detection.
What are the potential side effects?
Potential side effects from interventions may include discomfort or pain during biopsy procedures, bleeding or infection at the biopsy site, anxiety from undergoing diagnostic tests, and possible false positive/negative results leading to emotional distress.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Most efficient algorithm for detection of anogenital human papillomavirus (HPV)-related cancers and high-grade squamous intraepithelial lesions (HSIL)
Other study objectives
Artificial intelligence-based algorithm sensitivity, specificity, and negative and positive predictive values for cervical cancers and precancers

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Imaging, biospecimen collection, anoscopy and/or colposcopyExperimental Treatment6 Interventions
Patients undergo collection of cervical images (if applicable), 3 cervical anal swabs (if applicable) and 3 anal swabs for real-time testing of HPV or hrHPV over 90 minutes. Patients with a positive HPV or hrHPV test on undergo biopsies of visible lesions. Patients with a negative hrHPV test on their cervical swab may undergo a colposcopy. Patients with a positive hrHPV test on their anal swab undergo high-resolution anoscopy at a later visit within 1 month. Patients with a negative hrHPV on their anal swabs may undergo a high-resolution anoscopy and biopsies of visible lesions, and those with a positive anal cytology for LSIL or worse undergo a high-resolution anoscopy and biopsies within 1 month. Patients may be given a diagnosis and treatment at the second visit. Patients diagnosed with HSIL may undergo SOC treatment or enroll in additional studies when they are open to accrual
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
High Resolution Anoscopy
2010
N/A
~620
Biopsy
2014
Completed Phase 4
~1090
Colposcopy
2009
Completed Phase 3
~64500

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,570 Previous Clinical Trials
15,174,040 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,879 Previous Clinical Trials
41,011,746 Total Patients Enrolled
US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet)UNKNOWN
1 Previous Clinical Trials
619 Total Patients Enrolled

Media Library

Biospecimen Collection - Cervical Clinical Trial Eligibility Overview. Trial Name: NCT05074264 — N/A
Cervical Cancer Research Study Groups: Imaging, biospecimen collection, anoscopy and/or colposcopy
Cervical Cancer Clinical Trial 2023: Biospecimen Collection - Cervical Highlights & Side Effects. Trial Name: NCT05074264 — N/A
Biospecimen Collection - Cervical 2023 Treatment Timeline for Medical Study. Trial Name: NCT05074264 — N/A
~81 spots leftby Dec 2024